Skip to main content

Advertisement

SpringerLink
Log in

Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment

  • Educational Series
  • Advances in Clinical Management and Therapy of Cancer
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Introduction

Prostate cancer (PC) is one of the tumours with the highest incidence in recent years. PC therapies have several adverse effects. A panel consensus recommendation has been made to prevent or ameliorate complications in PC treatment to improve quality of life.

Material and methods

Fifteen specialists have met to analyse the different toxicities associated with PC treatment. Each medical specialist performed a National Library of Medicine PubMed search citations searching about these secondary effects and his speciality from 1999 to 2009 to propose measures for their prevention/amelioration.

Results

Surgery is associated with incontinence and impotence. Radiotherapy can produce acute, late urological and gastrointestinal toxicity. Brachytherapy can produce acute urinary retention. Chemotherapy is associated with haematotoxicity, peripheral neuropathy and diarrhoea, and hormone therapy can produce osteoporosis, metabolic syndrome, cognitive and muscular alterations, cardiotoxicity, etc.

Conclusions

Improvement in surgical techniques and technology (IMRT/IGRT) can prevent surgical and radiotherapeutic toxicity, respectively. Brachytherapy toxicity can be prevented with precise techniques to preserve the urethra. Chemotherapy toxicity can be prevented with personalised schedules of treatment and close follow-up of iatrogenia and hormone therapy toxicity can be prevented with close follow-up of possible secondary effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Autier M, Boniol M et al (2007) Estimates of cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592

    Article  CAS  PubMed  Google Scholar 

  2. Draisma G, Etzioni R, Tsodikov A et al (2009) Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101:374–383

    Article  PubMed  Google Scholar 

  3. Catalona W, Loeb S (2005) The PSA era is not over for prostate cancer. Eur Urol 48:541–545

    Article  PubMed  Google Scholar 

  4. Stanford JL, Feng Z, Hamilton AS et al (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 283:354–360

    Article  CAS  PubMed  Google Scholar 

  5. Sacco E, Prayer-Galetti T, Pinto F et al (2006) Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. BJU Int 97:1234–1241

    Article  PubMed  Google Scholar 

  6. Besarani D, Amoroso P, Kirby R (2004) Bladder neck contracture after radical retropubic prostatectomy. BJU Int 94:1245–1247

    Article  PubMed  Google Scholar 

  7. Marberger M, Carroll PR, Zelefsky MJ et al (2008) New treatments for localized prostate cancer. Urology 72:836–843

    Article  Google Scholar 

  8. Zietman AL, DeSilvio ML, Slater JD et al (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate a randomized controlled trial. JAMA 294:1233–1239

    Article  CAS  PubMed  Google Scholar 

  9. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346

    CAS  PubMed  Google Scholar 

  10. Zapatero A, García-Vicente F, Modolell I et al (2004) Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect. Int J Radiat Oncol Biol Phys 59:1343–1351

    PubMed  Google Scholar 

  11. García-Vicente F, Zapatero A, Floriano A et al (2005) Statistical analysis of dose-volume and dose-wall histograms for rectal toxicity following 3D-CRT in prostate cancer. Med Phys 32:2503–2509

    Article  PubMed  Google Scholar 

  12. Christie D, Denham J, Steigler A et al (2005) Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short-term neo-adjuvant androgen deprivation. Radiother Oncol 77:117–125

    Article  PubMed  Google Scholar 

  13. Karazindiyanoglu S, Cayan S (2008) The effect of testosterone therapy on lower urinary tract symptoms and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male 11:146–149

    Article  CAS  PubMed  Google Scholar 

  14. Wernicke AG, Valicenti R, Dieva K et al (2004) Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three dimensional conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 60:1357–1363

    Article  PubMed  Google Scholar 

  15. Mangar SA, Sydes MR, Tucker HL et al (2006) Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer. Radiother Oncol 80:355–362

    Article  PubMed  Google Scholar 

  16. Sylvester J, Blasko JC, Grimm P et al (2007) 15 year biochemical relapse free survival in clinical stage T1-3 prostate cancer following combined external beam radiotherapy and brachytherapy: Seattle experience. Int J Radiat Oncol Biol Phys 67:57–64

    PubMed  Google Scholar 

  17. Stock R, Cahlon O, Cesaretti J et al (2004) Combined modality treatment in the management of high risk prostate cancer Int J Radiat Oncol Biol Phys 59:1352–1359

    PubMed  Google Scholar 

  18. Merrick G, Butler W, Wallner K et al (2003) Dysuria after permanent implant brachytherapy. Int J Radiat Oncol Biol Phys 55:979–985

    PubMed  Google Scholar 

  19. Gutman S, Merrick G, Butler W et al (2006) Severity categories of the international prostate symptom score before and urinary morbidity after permanent prostate brachytherapy. BJU Int 97:62–68

    Article  PubMed  Google Scholar 

  20. Shah SA, Cima RR, Benoit E et al (2004) Rectal complications after prostate brachytherapy. Dis Colon Rectum 47:1487–1492

    PubMed  Google Scholar 

  21. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  CAS  PubMed  Google Scholar 

  22. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Article  CAS  PubMed  Google Scholar 

  23. Debes JD, Tindall DJ (2004) Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351:1488–1490

    Article  CAS  PubMed  Google Scholar 

  24. Huggins C, Hodges CV (1941) The effect of castration and estrogen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–299

    CAS  Google Scholar 

  25. Shahinian VB, Kuo YF, Freeman JL et al (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate cancer. Cancer 103:1615–1624

    Article  CAS  PubMed  Google Scholar 

  26. Da Silva FC, Reis E, Costa T et al (1993) Quality of life in patients with prostatic cancer. A feasibility study. The Members of quality of life Committee of the EORTC Genitourinary Group. Cancer 71:1138–1142

    Article  PubMed  Google Scholar 

  27. Potosky AL, Reeve BB, Clerg LX et al (2002) Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or non therapy. J Natl Cancer Inst 88:430–437

    Google Scholar 

  28. Ferrer F, Casas F, Biete A (2005) Impacto de la edad y de la comorbilidad en el paciente irradiado con cáncer de próstata. Med Clin (Barc) 125:121–126

    Article  Google Scholar 

  29. Townsend MF (1997) Bone fractures associated with luteinzing hormone-releasing hormone agonists used in the treatment of prostate cancer. Cancer 79:545–550

    Article  CAS  PubMed  Google Scholar 

  30. Smith M, McGovern FJ, Fallon MA et al (2001) Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer 91:2238–2245

    Article  CAS  PubMed  Google Scholar 

  31. Rueda S, Serra-Prat M, Fernández C et al (2008) Metabolic syndrome and cardiovascular disease in elders: results of the Mataró Ageing study. Med Clin (Barc) 130:327–331

    Article  Google Scholar 

  32. (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497

  33. International Diabetes Federation (2005) The IDF consensus worldwide definition of the metabolic syndrome [article online]. Available at: http://www.idf.org/webdata/docs/metac_syndrome_def.pdf

  34. Selvin E (2007) Androgens and diabetes in men. Results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 30:234–238

    Article  CAS  PubMed  Google Scholar 

  35. Braga-Basaria M, Dobs A, Muller D et al (2006) Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24:3979–3983

    Article  PubMed  Google Scholar 

  36. Basaria S, Muller D, Carducci M et al (2007) Relation between duration of androgen deprivation therapy and degree of insulin resistance in men prostate cancer. Arch Intern Med 167:612–613

    Article  PubMed  Google Scholar 

  37. Smith J, Bennett S, Evans L et al (2003) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261–4267

    Article  Google Scholar 

  38. Basaria S, Muller D, Carducci M et al (2006) Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgendeprivation therapy. Cancer 106:581–588

    Article  CAS  PubMed  Google Scholar 

  39. Matthew R, Smith MR, Lee H et al (2008) Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer. Differences from the classic metabolic syndrome. Cancer 112:2188–2194

    Article  CAS  Google Scholar 

  40. Cherrier MM, Asthana S, Plymate S et al (2001) Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 57:80–88

    CAS  PubMed  Google Scholar 

  41. Kumar RJ, Barqawi A, Crawford D (2005) Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 7[Suppl 5]:S37–S43

    PubMed  Google Scholar 

  42. Cherrier MM, Rose AL, Higano C (2003) The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 170:1808–1811

    Article  CAS  PubMed  Google Scholar 

  43. Salminen E, Portin R, Koskinen A (2005) Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 103:1381–1387

    Article  PubMed  Google Scholar 

  44. Jenkins VA, Bloomfield DJ, Shilling VM et al (2005) Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int 96:48–53

    Article  CAS  PubMed  Google Scholar 

  45. Joly F, Alibhai S, Galica J et al (2006) Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol 176:2443–2447

    Article  CAS  PubMed  Google Scholar 

  46. Peters C, Lotzerich H, Niemeier B et al (1995) Exercise cancer and the immune response of monocytes. Anticancer Res 15:175–179

    CAS  PubMed  Google Scholar 

  47. Keating NL, O’Malley J, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448–4456

    Article  CAS  PubMed  Google Scholar 

  48. D’Amico AV, Dedham JW, Crook J et al (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of a fatal myocardial infarction. J Clin Oncol 25:2420–2425

    Article  PubMed  CAS  Google Scholar 

  49. Efstathiou JA, Bae K, Shipley WU et al (2009) Cardiovascular mortality and duration of androgen deprivation advanced prostate cancer: Analysis of RTOG 85-31. J Clin Oncol 27:92–99

    Article  PubMed  Google Scholar 

  50. D’Amico AV, Chen M-H, Renshaw AA et al (2008) Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer 113:3290–3297

    Article  PubMed  Google Scholar 

  51. D’Amico AV, Chen MH, Renshaw AA et al (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299:289–295

    Article  PubMed  Google Scholar 

  52. Efstathiou JA, Bae K, Shipley WU et al (2008) Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54:816–824

    Article  CAS  PubMed  Google Scholar 

  53. Liu PY, Death AK, Handelsman DJ (2003) Androgens and cardiovascular disease. Endocr Rev 24:313–340

    Article  CAS  PubMed  Google Scholar 

  54. Wu F, von Eckardstein A (2003) Androgens and coronary artery disease. Endocr Rev 24:183–217

    Article  CAS  PubMed  Google Scholar 

  55. Smith JC, Bennett S, Evans M et al (2001) The effects of induced hypogonadism on arterial stiffnes, body composition and metabolic parameters in male with prostate cancer. J Clin Endocr Metabol 86:4261–4267

    Article  CAS  Google Scholar 

  56. Trachtenberg J, Gittleman M, Steidle C (2002) A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 167:1670–1674

    Article  CAS  PubMed  Google Scholar 

  57. Asbell SO, Leon SA, Tester WJ et al (1996) Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 29: 243–248

    Article  CAS  PubMed  Google Scholar 

  58. D’Amico AV, Saegart T, Chen M et al (2002) Initial decline in haemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. Cancer 95: 275–280

    Article  PubMed  Google Scholar 

  59. Pai HH, Ludgate C, Pickles T et al (2006) Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapy. Int J Radiat Oncol Biol Phys 65:990–998

    CAS  PubMed  Google Scholar 

  60. Chatelin C, Rousseau V, Cosaert J (1994) French multicenter trial comparing Casodex monotherapy with castration plus nilutamide in metastatic prostate cancer a preliminary report. Eur Urol 26:10–14

    Google Scholar 

  61. Harris MG, Coleman SG, Faulds D et al (1993) Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. Drugs Aging 3:2–25

    Article  Google Scholar 

  62. Matsuzaki Y, Nagai D, Ichimura E et al (2006) Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice. J Gastroenterol 41:231–239

    Article  CAS  PubMed  Google Scholar 

  63. Kattan J, Spatz A, Culine S et al (1994) Hepatocellular carcinoma during hormonotherapy for prostatic cancer. Am J Clin Oncol 17:390–392

    Article  CAS  PubMed  Google Scholar 

  64. Gaker DL, Steel BL (2004) Radical prostatectomy with preservation of urinary continence: pathology and long-term results. J Urol 172:2549–2552

    Article  PubMed  Google Scholar 

  65. Eichelberg C, Erbersdobler A, Michl U et al (2007) Nerve distribution along the prostatic capsule. Eur Urol 51:105–110

    Article  PubMed  Google Scholar 

  66. Kessler TM, Burkhard FC, Studer UE (2007) Nerve-sparing open radical retropubic prostatectomy. Eur Urol 51:90–97

    Article  PubMed  Google Scholar 

  67. Roach M III, DeSilvio M, Lawton C et al (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 15:1904–1911

    Article  Google Scholar 

  68. Roach M III, Marquez C, Yuo HS et al (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1:2833–2837

    Google Scholar 

  69. Nutting CM, Convery DJ, Cosgrove VP et al (2000) Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 48:649–656

    CAS  PubMed  Google Scholar 

  70. Ferrer F, Suárez JF, Guedea F et al (2008) Health-related quality of life 2 years alter treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 72:421–432

    PubMed  Google Scholar 

  71. Lin AM, Ryan CJ, Small E (2007) Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Haematol 61:243–254

    Article  Google Scholar 

  72. Bellmunt J, Albiol S, Albanell J (2007) Intermit tent chemotherapy in metastatic androgen-independent prostate cancer. BJU Int 100:490–492

    Article  CAS  PubMed  Google Scholar 

  73. Lord R, Nair S, Schache A et al (2007) Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 177:2136–2140

    Article  CAS  PubMed  Google Scholar 

  74. Moyad MA (2002) Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research. Urology 59:34–40

    Article  PubMed  Google Scholar 

  75. Ringe JD, Faber H, Farahmand P, Dorst A (2006) Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26:427–431

    Article  CAS  PubMed  Google Scholar 

  76. Finkelstein JS, Hayes A, Hunzelman JL et al (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226

    Article  CAS  PubMed  Google Scholar 

  77. Dawson-Hughes B, Harris SS, Krall EA et al (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670–676

    Article  CAS  PubMed  Google Scholar 

  78. Pedersen SJ, Borgbjerg FM, Schousboe B et al (2008) A comprehensive hip fracture program reduces complication rates and mortality J Am Geriatr Soc 56:1831–1838

    Article  PubMed  Google Scholar 

  79. Diamond TH, Winters J, Smith A et al (2001) The antiosteoporotic efficacy of intravenous Pamidronate in men with prostate carcinoma receiving combined androgen blockade. A double blind, randomized, placebo-controlled crossover study. Cancer 92:1444–1450

    Article  CAS  PubMed  Google Scholar 

  80. Smith MR, McGovern FJ, Zietman AL et al (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948–955

    Article  CAS  PubMed  Google Scholar 

  81. Smith MR, Eastham J, Gleason DM et al (2003) Randomized controlled trial of Zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008–2012

    Article  CAS  PubMed  Google Scholar 

  82. Higano CS (2003) Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol 21:392–398

    CAS  PubMed  Google Scholar 

  83. Smith MR (2005) Selective estrogen receptor modulators to prevent treatment-related osteoporosis. Rev Urol 7:[Suppl 3]:S30–35

    PubMed  Google Scholar 

  84. Smith MR, Malkowicz SB, Chu F et al (2008) Toremefine increases bone mineral density in men rceiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Urol 179:152–155

    Article  CAS  PubMed  Google Scholar 

  85. Ibáñez J, Izquierdo M, Argüelles I et al (2005) Twice-weekly progressive resistance training decrease abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care 28:662–667

    Article  PubMed  Google Scholar 

  86. Salas-Salvado J, Fernández-Ballart J, Ros E et al (2008 Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: one year results of the PREDIMED randomised trial. Arch Intern Med 168:2249–2258

    Article  Google Scholar 

  87. Jonson J, Lane C (1993) Role of support groups in cancer care. Support Care Cancer 1:52–56

    Article  Google Scholar 

  88. Berglund G, Petersson LM, Eriksson K et al (2003) “Between men”: patient perceptions and priorities in a rehabilitation program for men with prostate cancer. Patient Educ Couns 49:285–292

    Article  PubMed  Google Scholar 

  89. Moinpour CM, Savage MJ, Troxel A et al (1998) Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 90:1537–1544

    Article  CAS  PubMed  Google Scholar 

  90. Penedo FJ, Molton I, Dahn JR et al (2006) A randomized clinical trial of group-based cognitivebehavioral stress management in localized prostate cancer: development of stress management skills improves quality of life and benefit finding. Ann Behav Med 31:261–270

    Article  PubMed  Google Scholar 

  91. Galvao DA (2007) Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer Prostatic Dis 10:340–346

    Article  CAS  PubMed  Google Scholar 

  92. Ibañez J, Izquierdo M, Argüelles I et al (2005) Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care 28:662–667

    Article  PubMed  Google Scholar 

  93. Izquierdo M, Häkkinen K, Ibañez J et al (2001) Effects of strength training on muscle power and serum hormones in middle-aged and older men. J Appl Physiol 90:1497–1507

    CAS  PubMed  Google Scholar 

  94. Roth SM (2001) Muscle size response to strength training in young and older men and women. J Am Geriatr Soc 49:1428–1433

    Article  CAS  PubMed  Google Scholar 

  95. Galvao DA, Newton RU (2005) Review of exercise intervention studies in cancer patients. J Clin Oncol 23:899–909

    Article  PubMed  Google Scholar 

  96. Smith MR, Malkowicz SB, Chu F et al (2008) Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 26:1824–1829

    Article  CAS  PubMed  Google Scholar 

  97. Padula GA, Zelelfsky MJ, Venkatraman ES et al (2002) Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 52:439–443

    CAS  PubMed  Google Scholar 

  98. Bogdanos J, Karamanolakis D, Milathianakis C et al (2003) Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement. Anticancer Res 23:1757–1762

    CAS  PubMed  Google Scholar 

  99. Feldman L, Wang Y, Rhim JS et al (2006) Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 66:135–145

    Article  CAS  PubMed  Google Scholar 

  100. Galvao DA, Nasaka K, Taaffe DR et al (2006) Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 38:2045–2052

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Oncology Department, Hospital Clínic, C/ Villarroel, 170, ES-08036, Barcelona, Spain

    Francesc Casas

  2. Health Department, Generalitat de Catalunya, Barcelona, Spain

    Josep María Borràs

  3. Radiation Oncology Department Institut Català d’Oncologia, Hospitalet de Llobregat, Barcelona, Spain

    Ferran Ferrer

  4. Rheumatology Department, Hospital Clínic, Barcelona, Spain

    Núria Guanyabens

  5. Urology Department, Hospital Clínic, Barcelona, Spain

    Rafael Gutiérrez del Pozo & María José Ribal

  6. Medical Oncology Department (Psychoncology), Hospital de Terrassa, Terrassa, Barcelona, Spain

    Concha León

  7. Torrecilla Radiation Oncology Department, ERESA Hospital General Universitario, Valencia, Spain

    José López Torrecilla

  8. Medical Oncology Department, Hospital Clínic, Barcelona, Spain

    Begoña Mellado

  9. Urology Department, Hospital de la Vall d’Hebrón, Barcelona, Spain

    Joan Morote

  10. Endocrinology Department, Hospital Clínic, Barcelona, Spain

    Manel Puig

  11. Restaurant Sant Pau, Sant Pol de Mar, Barcelona, Spain

    Carme Ruscalleda

  12. Sport Medicine Department, Universitat Autonoma de Barcelona, Barcelona, Spain

    Agustí Serra

  13. Cardiology Department, Hospital Clínic, Barcelona, Spain

    Valentí Valls

  14. Radiation Oncology Department, Hospital Universitario la Princesa, Madrid, Spain

    Almudena Zapatero

Authors
  1. Francesc Casas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josep María Borràs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ferran Ferrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Núria Guanyabens
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rafael Gutiérrez del Pozo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Concha León
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. José López Torrecilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Begoña Mellado
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Joan Morote
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Manel Puig
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. María José Ribal
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Carme Ruscalleda
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Agustí Serra
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Valentí Valls
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Almudena Zapatero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesc Casas.

Additional information

Supported by an unrestricted educational grant from MSD Oncology

Rights and permissions

Reprints and permissions

About this article

Cite this article

Casas, F., Borràs, J.M., Ferrer, F. et al. Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment. Clin Transl Oncol 12, 346–355 (2010). https://doi.org/10.1007/s12094-010-0516-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-010-0516-6

Keywords

Search

Navigation